

Full Body MRI Collaboration Agreement with BioScan 360

The Board of Directors of 333D Ltd (ASX:T3D or “**Company**”), a company specialising in the creation and management of digital assets, is pleased to announce it has entered into a pilot collaboration agreement with BioScan 360 to provide full-body MRI preventative healthcare services.

Overview of Collaboration Agreement

Under this pilot, patients will undergo full body MRI scans through BioScan 360, with 333D recording critical imaging and clinical data on the blockchain. This technology solution enables decentralised storage of sensitive medical records and ensures that secure, auditable ownership of the data is returned to the patient.

Importantly, 333D will be responsible for marketing the service, managing the medical records and digital assets on the blockchain and collecting service fees directly from patients. For each scan conducted, 333D will pay BioScan 360 a facility fee of \$1,000 with the Company retaining the balance as service revenue. Revenue per scan is expected to range between \$2,500 and \$4,000.

Full Body MRI

A full-body MRI is a world-class non-invasive diagnostic imaging examination used in early detection of conditions like cancer, cardiovascular issues, and neurological disorders without using radiation. The scans will be performed on 3T MRI machines with state-of-the-art imaging software ensuring detailed information with a quick scan time.

Market Opportunity

Preventative healthcare represents one of the fastest-growing sectors of the global health industry, with increasing consumer demand for early detection, wellness optimisation, and long-term health monitoring. Increased awareness surrounding longevity, an ageing population, and patient demand for personalised care are accelerating adoption of preventative diagnostic services such as full body MRI.

The global preventative healthcare tech and services market was valued at US\$243 billion in 2022, and is expected to reach US\$585 billion by 2030, growing at a compound annual growth rate of 11.8%.

333D believes this collaboration positions the Company at the intersection of digital health, blockchain technology, and preventative medicine, opening a pathway for scalable growth both in Australia and internationally.

Benefits of Blockchain-Based Medical Records

By recording MRI scan data on the blockchain, 333D provides patients with:

- **Data ownership and control** – Patients retain secure, auditable, and tamper-proof ownership of their medical records.

333D Limited

ABN 24 118 159 881

Level 23, Rialto South Tower,
525 Collins Street,
Melbourne VIC 3000 Australia



- **Privacy and security** – Sensitive health data is protected by decentralised storage protocols, reducing reliance on vulnerable centralised systems.
- **Portability** – Patients can seamlessly share their records with the medical professionals they choose across institutions and jurisdictions.
- **Continuity of care** – A verified history of medical imaging and diagnostic data is available over the long-term providing seamless access to longitudinal imaging.

Importance of Longitudinal Imaging

A key advantage of this pilot program is enabling the creation of a time-series dataset for each patient. Rather than relying on a single MRI scan at a particular point in time, patients will have medical data stored on the blockchain over time, enabling clinicians to identify subtle changes and early indicators of disease progression. This longitudinal view can provide:

- Earlier and more accurate diagnosis of emerging conditions.
- Improved ability to monitor treatment responses.
- More personalised and preventative healthcare outcomes.

National Growth Strategy

Subject to the successful performance of the pilot program, 333D intends to expand this offering nationally in collaboration with BioScan 360 and other leading healthcare institutions. This roll-out strategy will establish 333D as a leader in the application of blockchain and artificial intelligence to medical imaging and digital asset management.

In announcing the Collaboration Agreement, 333D Director, Dr Nigel Finch, said;

“This collaboration reflects 333D’s ongoing commitment to delivering cutting-edge healthcare solutions by merging advanced medical imaging with blockchain technology. By empowering patients to take control of their health data while offering both patients and medical professionals a secure and auditable platform for long-term analysis, 333D is at the forefront of the shift towards preventative and patient-centred care”

The Company looks forward to updating shareholders as this initiative progresses.

- END -

The release of this announcement was **authorised by the Board of Directors** of the Company.

About 333D Limited

333D Limited is a company that seeks to capitalise upon opportunities in the digital line of business as new technologies are developed from both digital capture and digital creation perspectives, that will lend themselves for use in a myriad of interfaces, both physical (3D printed) and/or across other or additional digital platforms. 333D specialises in the digital capture of a subject matter; digital creation of data files incorporating diagnostic or medical imaging in DICOM format, 2D, 3D and animated digital content including still photography, digital design and motion video; and encoding data files using artificial intelligence such that a digitally created file is generated that is viewable in a 3D format and capable of being printed by a 3D printer. 333D Limited also provides bespoke design and management of digital assets (including 3D print files) and bespoke 3D printing bureau services

To find out more about 333D visit 333D.co

For further enquiries please contact:

John Conidi – Chief Executive Officer & Managing Director
+61 (0) 411 773 101
john@333d.co